InvestorsHub Logo
icon url

Aqua

11/14/12 6:30 PM

#34497 RE: Drugdoctor #34496

While Elite develops its extended release opioids for FDA approval, other pharmaceutical companies will continue to elicit the services of Elite's expert technicians and its new facility to form mutual partnerships and to finance its R & D. In the long-run, this will lead the company to increased revenues and profitability, and to realize Elite's objectives to be uplisted to the Nasdaq with an FDA-approval for ELI-216. As stakeholders in Elite, all we can expect from Jerry and the rest of his team is be honest with us and to uphold ethical standards, and to be deligient in executing their business plan while implementing contigency plans to overcome the challenges that we meet. Stay the course and Cheers!